Form 4: Eton Pharmaceuticals Director Acquires 25,000 Stock Options

Eton Pharmaceuticals director Paul V. Maier was granted 25,000 employee stock options on January 3, 2025.

Summary

• Paul V. Maier, a director at Eton Pharmaceuticals, was granted 25,000 employee stock options on January 3, 2025.
• The options have an exercise price of $13 per share.
• The options vest quarterly over 12 months, becoming fully exercisable on January 3, 2026.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, which is generally neutral to positive. The grant of options is a positive sign of alignment between management and shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating directors in publicly traded companies like Eton Pharmaceuticals.
• The vesting schedule of 12 months is fairly typical for such grants.
• The exercise price of $13 is a key factor in determining the value of the options.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the company performs well and the options become valuable.

Key Dates

Keywords

stock options, insider trading, Eton Pharmaceuticals, director, equity compensation, Form 4